Indirect purchasers seek nod for settlement with Jazz Pharmaceuticals in US Xyrem antitrust case
MLex Summary: Indirect purchasers of Xyrem asked a US federal judge to grant preliminary approval to their $145 million settlement with Jazz Pharmaceuticals to resolve antitrust claims.See attached file. ...To view the full article, register now.
Already a subscriber? Click here to view full article